Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neck
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Oct 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2015 Status changed from not yet recruiting to recruiting, according to University Hospital Medical Information Network - Japan.